pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·Aug 24·1 min read
save

Health Secretary Kennedy criticizes CDC vaccine classification scheme and shared decision-making category

Aug 24, 2026·read at BioSpace ↗RegulatoryNegative

Robert F. Kennedy Jr., serving as Health Secretary, has raised concerns about how the CDC categorizes vaccine recommendations.

The CDC uses three categories: routine recommendations for universal use, risk‑based recommendations, and a shared clinical decision‑making (SCDM) category where doctors discuss options with patients or guardians.

Kennedy argues that the SCDM category may unintentionally suggest that parental consent or clinical discussion is not required for the other two categories, potentially undermining informed consent.

He highlighted this issue in a recent Request for Information filed with the Federal Register, following a prior directive from former President Trump to separate the MMR vaccine.

The challenge could prompt a review of how vaccine guidance is presented, though no regulatory change has been announced yet.

source

This writeup was produced by pharmadog from original reporting by BioSpace.

Original headline: “Kennedy questions vaccination guidelines following Trump’s order to break up MMR”

read at BioSpace ↗
587 words · retrieved Aug 24
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PFIZERSanofi
topics
Vaccine16Vaccines11

related stories

  • Sep 3US to grant up to $125M for personalized RNA manufacturing innovationBioSpace
  • Aug 26Inside the Gulf biotech deal model, ahead of RGMBS 2026 in RiyadhBioSpace
  • Jul 17Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advancesBioPharma Dive
  • Jul 16Updated: Sanofi, Arbutus file separate suits against mRNA vaccine makers over LNP tech patentsEndpoints
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive